In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

Thomas O'Hare, Denise K. Walters, Eric P. Stoffregen, Taiping Jia, Paul W. Manley, Jürgen Mestan, Sandra W. Cowan-Jacob, Francis Y. Lee, Michael C. Heinrich, Michael W.N. Deininger, Brian J. Druker

Research output: Contribution to journalArticle

841 Scopus citations

Fingerprint Dive into the research topics of 'In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants'. Together they form a unique fingerprint.

Medicine & Life Sciences